Curis reports Q2 EPS ($2.03), consensus ($1.67)

Reports Q2 revenue $2.5M, consensus $2.06M. Curis expects its existing cash, cash equivalents and investments will enable its planned operations into Q1. “We are pleased with our progress in the TakeAim Lymphoma study and look forward to providing updated data at the ASH conference in December. As we continue the expansion of clinical sites in our PCNSL study, we have initiated discussions with health authorities to align on a registrational development path for emavusertib in PCNSL. We are excited to take this next step in advancing a novel treatment for patients with PCNSL,” said James Dentzer, CEO.